Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations

Area of Science:

• Pharmacogenetics
• Clinical Pharmacology
• Drug Development

Background:

• Pharmacogenetics (PGt) is rapidly advancing but clinical applications, particularly for pediatric indications, lag behind.
• Current research often isolates PGt factors, neglecting their interaction with other drug response determinants like age and renal function.

Purpose of the Study:

• To highlight the misalignment between PGt research and clinical labeling requirements, especially for pediatric drug use.
• To advocate for improved study designs and data analysis methodologies to integrate PGt findings into drug labels.

Main Methods:

• Review of current pharmacogenetics research practices and their limitations.
• Discussion of challenges in pediatric clinical research and potential solutions.
• Emphasis on the need for model-based methodologies in data analysis.

Main Results:

• Existing PGt research protocols often treat genetic factors in isolation, not as covariates alongside clinical factors.
• Lack of clear guidelines hinders the incorporation of PGt findings into drug labels.
• Pediatric research presents unique challenges that require advanced methodological approaches.

Conclusions:

• A collaborative effort among academia, industry, and regulatory agencies is essential to revise study design and data analysis standards.
• Implementing model-based methodologies will enable accurate interpretation of PGt results.
• This will facilitate appropriate labeling recommendations, maximizing PGt's potential in drug development and prescription.